# BPC-157 TB-500 FAQ: Evidence, Safety, Dosage, and Legal Status

> BPC-157 TB-500 FAQ — the common questions answered straight from the literature: synergy, side effects, the cancer question, half-life, reconstitution, and the FDA 503A and WADA status. Every quantitative answer cited.

The full question inventory, answered off the published record — definitional, mechanistic, dosing, safety, and regulatory, each answer posted as a position with its source.

## Definitions and overview

### What is the Wolverine peptide blend?
The Wolverine peptide blend is a research-community name for a two-peptide pairing of BPC-157 and TB-500, marketed and discussed as a tissue-repair "stack" [1][3]. It is not a single chemical entity or an approved product, and it has no validated combination dose or controlled human trial [8].

### What is BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid pentadecapeptide (`GEPPPGKPADDAGLV`) derived from a human gastric-juice protein, the cytoprotective and angiogenic component [1][2]. TB-500 is a synthetic `Ac-LKKTETQ` heptapeptide from the actin-binding region of Thymosin Beta-4, the cytoskeletal cell-migration component [3][7].

### What is the BPC-157 and TB-500 blend used for in research?
In research, the constituents are studied for tissue repair — BPC-157 in tendon, gut, and ischemia models [1][2], and Thymosin Beta-4 in wound, cardiac, and migration models [4]. The blend itself has no validated research protocol; no peer-reviewed combination study defines a dose, ratio, or endpoint [8].

## Mechanism and comparison

### How does TB-500 work (actin / Thymosin Beta-4)?
TB-500's `Ac-LKKTETQ` motif binds monomeric G-actin 1:1, and crystallography showed Thymosin Beta-4 sequesters the actin monomer by capping both ends, regulating the cytoskeletal dynamics behind cell migration [3]. Most efficacy data attributed to "TB-500" used full-length Thymosin Beta-4, not the fragment [4].

### How does BPC-157 work compared to TB-500?
BPC-157 acts extracellularly and vascularly — up-regulating VEGFR2 and activating Akt-eNOS to drive angiogenesis and cytoprotection [2]. TB-500 acts intracellularly on the cytoskeleton, sequestering G-actin to regulate migration [3]. Different, complementary pathways — the stated basis for pairing them [1][3].

### What is the difference between BPC-157 and TB-500?
BPC-157 (~1419.5 Da) is a gastric-juice-derived pentadecapeptide that signals angiogenesis and cytoprotection [1][2]; TB-500 (~889.0 Da) is a Thymosin-Beta-4 fragment that regulates actin and cell migration [3]. They differ in size, origin, and mechanism, and most TB-500 data are from the full-length protein [4][7].

### Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?
Yes, by distinct routes. BPC-157 up-regulates VEGFR2 and activates VEGFR2-Akt-eNOS, raising vessel density and blood-flow recovery in ischemia models [2]. Thymosin Beta-4 promotes endothelial migration and angiogenesis, with VEGF/HIF-1alpha reported for the full-length protein [4].

## Dosage and administration

### What is the half-life of BPC-157 and TB-500?
No validated human half-life exists for either constituent or the blend. BPC-157's elimination half-life was under 30 minutes in a rat/dog study; human intravenous Thymosin Beta-4 showed dose-proportional pharmacokinetics with half-life rising at higher doses [5][6], but the TB-500 heptapeptide has no established half-life.

### How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both peptides are supplied lyophilized and reconstituted in bacteriostatic or sterile water for research handling, then refrigerated. This site does not provide volumes or instructions; product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed.

### How often should you inject BPC-157 and TB-500?
There is no validated injection frequency for the blend. Rodent efficacy studies used model-specific intraperitoneal schedules [1][3]; human data are single-agent intravenous Thymosin Beta-4 [5][6]. Community frequency protocols are not derived from controlled trials.

### How do you cycle BPC-157 and TB-500?
No controlled human trial defines a cycle. "Loading then maintenance" cycling is a community convention without a controlled-trial basis [8], and the constituent studies used fixed animal schedules, not translatable human cycles.

## Safety

### What are the side effects of BPC-157 and TB-500?
A 2025 systematic review of BPC-157 found "no clinical safety data" from controlled human trials [8], and there is no combination safety dataset. Human safety data exist only for full-length Thymosin Beta-4, which was well tolerated to `1260 mg` intravenously with no serious adverse events in Phase 1 [5][6]. That does not establish the safety of the TB-500 fragment, the blend, or research-community routes.

### Does TB-500 cause cancer or promote tumor growth?
This is a theoretical safety signal, not a demonstrated human effect. Thymosin Beta-4 is overexpressed in several cancers and implicated in metastasis and tumor angiogenesis, so the same pro-migratory, pro-angiogenic properties that aid repair could in principle support tumor progression [4] — a concern that compounds when two pro-repair peptides are combined. No human study has measured this risk for TB-500 or the blend.

### Is the 'Wolverine' synergy claim actually proven?
No. The synergy claim is an extrapolation from each peptide's separate, largely non-overlapping mechanism [1][3]. No controlled combination study defines a synergistic dose, ratio, or endpoint, and a 2025 BPC-157 systematic review makes no mention of TB-500 or combination use [8].

## Community and regulatory

### BPC-157 TB-500 reddit
Reddit and forum threads on BPC-157 TB-500 mostly trade anecdotes and community "loading" protocols, which this site does not reproduce as guidance. The published record is narrower than the forum consensus: constituent findings are largely preclinical, the "TB-500" human data are for full-length Thymosin Beta-4 [5][6], and no controlled combination trial exists [8]. Where forum claims and the literature diverge, this terminal posts the literature.

### Is Wolverine legal?
Neither component is an FDA-approved drug, and both are currently 503A Category 2 bulk substances, so compounding-pharmacy access is restricted today [11][12]. Both are on a scheduled July 23-24, 2026 FDA advisory-committee agenda for evaluation [13], and both are WADA-prohibited [14]. See the [Wolverine legal status](/legal-status) page; this is general information, not legal advice.

### Can you get BPC-157 from a compounding pharmacy?
Not through routine 503A compounding while its current status stands. BPC-157 is a 503A Category 2 bulk substance, which FDA does not cover under the enforcement-discretion policy that applies to Category 1 [11][12]. Lawful compounded access generally requires a licensed-prescriber evaluation, a valid prescription, and an ingredient eligible under the 503A/503B rules [12].

### What is the FDA 503A status of Wolverine?
Both components are 503A Category 2 — bulk drug substances FDA identified as possibly presenting significant safety risks, effective the September 29, 2023 list update [11]. Both BPC-157 and TB-500 are on the July 23-24, 2026 PCAC agenda as candidates being considered for the 503A bulks list, a scheduled evaluation rather than a change in current status [13].

---

A two-position evidence board for the BPC-157 TB-500 blend — each constituent finding posted up where the studies confirm it and down where the combination row stays empty, the FDA 503A and WADA status read off first, and nothing here listed, priced, or for sale.